{"prompt": "['2016N277425_03', 'CONFIDENTIAL', '2018N377698_00', '201749', 'Section 12.4.6 Reporting of SAEs to GSK', 'Rationale for change: Integration of Canadian Amendment 2 into main protocol', 'Revised text: Reporting Specific to Canada: For lack of efficacy reports, the paper', 'form will be used to submit to GSK as per the table in Section 12.4.1 above.', 'Section 12.5.2 COPD Exacerbation Severity', 'Rationale for change: clarify chest x-rays performed in the context of the protocol', 'Revised text:Every effort should be made to conduct a chest x ray within 48 hours', 'of identification of a moderate or severe exaccrbation. Chest X-Ray for pneumonia', 'and/or moderate/severe exacerbation is not mandated but can be performed if required by', 'the investigator as part of standard care of subjects.', 'Section 12.8 Appendix 8: Country Specific Requirements', 'Rationale for change: Integration of Canadian Amendment 2 into main protocol', 'Revised text: In Canada only, additions were made to Section 7.4.1 and Appendix 4 to', 'comply with Health Canada guidelines concerning the requirement of pharmaceutical', 'manufacturers to expeditiously report domestic cases of unusual failure in efficacy', '(UFIE) for new drugs to the Marketed Health Products Directorate (MHPD) within', '15 days of first notification.', 'No country specifie requirements exist.', '108']['2016N277425_02', 'CONFIDENTIAL', '2018N377698_00', 'The GlaxoSmithKline group of companies', '201749', 'TITLE PAGE', 'Division: Worldwide Development', 'Information Type: Protocol Amendment', 'Title:', 'A 24-week treatment, multi-center, randomized, double-blind,', 'double-dummy, parallel group study to compare', 'Umeclidinium/Vilanterol, Umeclidinium, and Salmeterol in', 'subjects with chronic obstructive pulmonary disease (COPD)', 'Compound Number:', 'GSK2592356', 'Development Phase:', 'IV', 'Effective Date:', '21-FEB-2017', 'Protocol Amendment Number: 02', 'Author (s):', 'PPD', 'Copyright 2017 the GlaxoSmithKline group of companies. All rights reserved.', 'Unauthorised copying or use of this information is prohibited.', '1']['2016N277425_02', 'CONFIDENTIAL', '2018N377698_00', 'The GlaxoSmithKline group of companies', '201749', 'Revision Chronology', 'GlaxoSmithKline', 'Date', 'Version', 'Document Number', '2016N277425_00', '2016-SEP-13', 'Original', '2016N277425_01', '2017-FEB-07', 'Amendment No. 1', 'This protocol amendment was created to make the following changes:', 'Regulatory Agency Identifying Number(s): A typographical error in the EudraCT no.', 'corrected. IND no. added', 'Section 4. 1 and Section 4.4: Typographical errors and inconsistencies corrected', 'Inconsistencies between Section 4.4, Section 7.3.1.5 and Section 7. 1revised', 'Section 7.1 Time and event table:', 'Un-intentional deletion of the (\"x\") were added to confirm that concomitant medications', 'should be reviewed at every clinic visit was corrected.', 'Increased the visit window', 'Typographical error and inconsistencies corrected as described in Appendix 9, Section', '12.9.', 'Section 7.2.2 Critical procedures performed at Screening (Visit 1): To clarify that height', 'and weight are collected at V1 \"Height and weight\" added', 'Section 7.3.2 Spirometry: \"At Screening, before the morning dose of usual COPD', \"medication(s)' added.\", 'Section 7.3.7: Physical activity monitor (study subset)', 'Inconsistency between Section 1, Section 4.1 and Section 7.3.7 revised', '2016N277425_02', '2017-FEB-21', 'Amendment No. 2', 'This protocol amendment was created to comply with Health Canada guidelines. They', 'require pharmaceutical manufacturers to expeditiously report domestic cases of unusual', 'failure in efficacy (UFIE) for new drugs to the Marketed Health Products Directorate', '(MHPD) within 15 days of first notification.', 'Changes were made to Section 7.4.1 and Appendix 4.', '2']\n\n###\n\n", "completion": "END"}